Uterine Fibroid Treatment Devices Market is estimated to be US$ 9.3 billion by 2034; Growing Prevalence of Uterine Fibroid Tumors to Fuel Market Growth

Uterine Fibroids are benign and non-cancerous and develop from uterus muscle tissues called myomas or leiomyomas, the most common type of growth found in women's pelvis. As per the American College of Obstetricians and Gynecologists, the study showed that fibroids occur mostly in African-American women than in white women. It also grows more rapidly in American women. Therefore, the chances of uterine fibroids are more in women in the coming years. Thus, the need for the proper treatment management for uterine fibroids is necessary in the future.

The most common treatment practices available in the market are myomectomy (surgical removal of fibroids while leaving the uterus in place) and hysterectomy (removal of the uterus). Moreover, additional treatment options for uterine fibroids besides medication and surgery are hysteroscopy, endometrial ablation, uterine artery embolization (UAE), and magnetic resonance imaging-guided ultrasound surgery, facilitating the demand for Uterine Fibroid Treatment Devices Market growth in coming years.

The report “Uterine Fibroid Treatment Devices Market, By Technology Type (Surgical Technique (Myomectomy and Hysterectomy), Laparoscopic techniques (Myolysis and Laparoscopic Myomectomy) Ablation Techniques (Cryoablation, Microwave Ablation, and Ultrasound Ablation (MRI-guided Focused Ultrasound (MRgFUS) and High Intensity Focused Ultrasound (HIFU)), Other Ablation Techniques) Embolization Techniques) By Mode of Treatment (Minimally Invasive Treatment, Invasive Treatment, and Non-Invasive Treatment), By End-User (Clinics, Hospitals, and Ambulatory Surgical Center), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034”

 Key Highlights:

• In May 2016, Hologic launched new “MyoSure Reach” device to provide better access and to help physicians to access and to remove hard-to-reach uterine fibroids. New launched “MyoSure Reach” is an improved device used for removing polyps and fibroids and also controls the bleeding.
• In February 2012, Apollo Hospitals launched new “MRI-HIFU” (MRI-guided high intensity focused ultrasound), a non-invasive technology for treating uterine fibroids. New launched technology is a non-invasive ablative process which helps all women in reproductive stage and offers good relief with no scarring, no post-operative complications and reduction in hospital stay.

Analyst View:

Technological advancement with new innovation and demand for minimally invasive surgeries has contributed the target market growth.  Further, rising research and development activities in the treatment of uterine fibroids will enhance the accuracy and precision of the medicines and devices in the coming years which is expected to boost the Uterine Fibroid Treatment Devices Market during the forecast period.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Uterine Fibroid Treatment Devices Market, By Technology Type (Surgical Technique (Myomectomy and Hysterectomy), Laparoscopic techniques (Myolysis and Laparoscopic Myomectomy) Ablation Techniques (Cryoablation, Microwave Ablation, and Ultrasound Ablation (MRI-guided Focused Ultrasound (MRgFUS) and High Intensity Focused Ultrasound (HIFU)), Other Ablation Techniques) Embolization Techniques) By Mode of Treatment (Minimally Invasive Treatment, Invasive Treatment, and Non-Invasive Treatment), By End-User (Clinics, Hospitals, and Ambulatory Surgical Center), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034”

Key Market Insights from the report:

Uterine Fibroid Treatment Devices Market accounted for US$ 7.2 billion in 2024 and is estimated to be US$ 9.3 billion by 2034 and is anticipated to register a CAGR of 2.90%. The Uterine Fibroid Treatment Devices Market is segmented based on Technology Type, Mode of Treatment, End-Users and Region.

• Based on Technology Type, Uterine Fibroid Treatment Devices Market is segmented into Surgical Technique, Laparoscopic Techniques, Ablation Techniques and Embolization Techniques.
• Based on Mode of Treatment, Uterine Fibroid Treatment Devices Market is segmented into Minimally Invasive Treatment, Invasive Treatment and Non-Invasive Treatment.
• Based on End-Users, Uterine Fibroid Treatment Devices Market is segmented into Clinics, Hospitals and Ambulatory Surgical Center.
• By Region, the Uterine Fibroid Treatment Devices Market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Competitive Landscape & their strategies of Uterine Fibroid Treatment Devices Market:

The prominent players operating in the Uterine Fibroid Treatment Devices Market includes, Boston Scientific Corporation, CONMED Corporation, PENTAX Medical, Advanced Surgical Concepts, PLLC, Ethicon, Inc., Hologic, Inc., Medtronic, Plc, CooperSurgical, Inc., Olympus Corporation, and Stryker Corporation.

To know more

Contact Us:

Sales

Prophecy Market Insights

U.S: 1 860 531 2574

RoW: 91 7775049802

Email- [email protected]

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com